Drug: infliximab, recombinant Quarter: 2016Q3
Total Records: 276 Number of Pages: 14
| DRUGNAME | PT | EventCount |
|---|---|---|
| INFLIXIMAB, RECOMBINANT | Disseminated tuberculosis | 5 |
| INFLIXIMAB, RECOMBINANT | Drug level decreased | 5 |
| INFLIXIMAB, RECOMBINANT | Acute respiratory failure | 4 |
| INFLIXIMAB, RECOMBINANT | Adverse drug reaction | 4 |
| INFLIXIMAB, RECOMBINANT | Anaphylactic reaction | 4 |
| INFLIXIMAB, RECOMBINANT | Antinuclear antibody positive | 4 |
| INFLIXIMAB, RECOMBINANT | Autoimmune hepatitis | 4 |
| INFLIXIMAB, RECOMBINANT | Cytomegalovirus colitis | 4 |
| INFLIXIMAB, RECOMBINANT | Cytomegalovirus infection | 4 |
| INFLIXIMAB, RECOMBINANT | Dizziness | 4 |
| INFLIXIMAB, RECOMBINANT | Double stranded DNA antibody | 4 |
| INFLIXIMAB, RECOMBINANT | Drug intolerance | 4 |
| INFLIXIMAB, RECOMBINANT | Drug resistance | 4 |
| INFLIXIMAB, RECOMBINANT | Extrapulmonary tuberculosis | 4 |
| INFLIXIMAB, RECOMBINANT | Neuroendocrine carcinoma of the skin | 4 |
| INFLIXIMAB, RECOMBINANT | Palpitations | 4 |
| INFLIXIMAB, RECOMBINANT | Seroconversion test positive | 4 |
| INFLIXIMAB, RECOMBINANT | Squamous cell carcinoma | 4 |
| INFLIXIMAB, RECOMBINANT | Wound infection | 4 |
| INFLIXIMAB, RECOMBINANT | Anaphylactoid reaction | 3 |
Total Records: 276 Number of Pages: 14